Oscillating PEP vs Autogenic Drainage in People With Bronchiectasis (oPEP-vs-AD)
Primary Purpose
Bronchiectasis
Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
oPEP
Autogenic drainage
Sponsored by
About this trial
This is an interventional treatment trial for Bronchiectasis
Eligibility Criteria
Inclusion Criteria:
- High Resolution chest computerized tomography (HRCT) during stable disease imaging bronchiectasis in at least 2 lung lobes
- Sputum production during most days of the year
- Stable chronic therapy during last 4 weeks
- FEV1 = 70% predicted or higher on spirometry
- Able to give informed consent or assent
- Age: 18- 80 years
Exclusion Criteria:
- An exacerbation during last 4 weeks before randomization
- Any change in respiratory medications during the past 4 weeks before randomization
- A diagnosis of cystic fibrosis
- A diagnosis of primary ciliary dyskinesia
Sites / Locations
- Carmel Medical CenterRecruiting
- Pulmonology Institute, Carmel Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Autogenic drainage
oPEP
Arm Description
Chest physiotherapy by autogenic drainage daily for 15 minutes each day, for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
Chest physiotherapy with an Aerobika oPEP device daily for 15 minutes each day for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
Outcomes
Primary Outcome Measures
Change in LCI
LCI will be determined before intervention and after 1 month and change will be recorded.
Secondary Outcome Measures
Total score on QOL- B questionnaire
Patients will answer QOL-B questionnaire before and after 1 month of the intervention, and total score will be recorded.
Score on respiratory domain of QOL-B questionnaire
Patients will answer QOL-B questionnaire before and after 1 month of the intervention, and score on respiratory domain will be recorded.
FEV1 (% predicted)- difference from baseline
Spirometry will be performed before and after 1 month of the intervention, and change in FEV1 (% of predicted) will be recorded.
Forced Expiratory Volume (FVC) (% predicted)- difference from baseline
Spirometry will be performed before and after 1 month of the intervention, and change in FVC (% of predicted) will be recorded.
Full Information
NCT ID
NCT03013452
First Posted
January 1, 2017
Last Updated
July 25, 2019
Sponsor
Carmel Medical Center
Collaborators
Rambam Health Care Campus
1. Study Identification
Unique Protocol Identification Number
NCT03013452
Brief Title
Oscillating PEP vs Autogenic Drainage in People With Bronchiectasis
Acronym
oPEP-vs-AD
Official Title
A Randomized Controlled Trial of Long Term Airway Clearance With Oscillating Positive End Expiratory Pressure Device Versus Autogenic Drainage in People With Bronchiectasis
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
March 9, 2017 (Actual)
Primary Completion Date
December 30, 2019 (Anticipated)
Study Completion Date
June 30, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Carmel Medical Center
Collaborators
Rambam Health Care Campus
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this study, investigating two modes of chest physiotherapy on lung clearance index (LCI), 50 patients with bronchiectasis will be randomized to either oPEP or autogenic drainage.
Detailed Description
One of the fundamental treatments in the management of bronchiectasis is airway clearance, which effectively rids the airways of mucus to prevent secondary infection and inflammation. While effective airway clearance is widely accepted as a first line treatment, the choice of airway clearance method is complicated by lacking evidence base. One of the obstacles to establishing evidence of efficacy of an airway clearance technique or device is the limitations in the choice of endpoints.
Aerobika (Trudell medical international, Canada) is an oscillating positive expiratory pressure (oPEP) device, designed and developed for the effective clearance of secretions in people with suppurative lung diseases. It has been tested and found safe and effective in chronic obstructive pulmonary disease (COPD) - chronic bronchitis.
The lung clearance index (LCI) measured by multiple breath washout (MBW) is a measure of ventilation inhomogeneity and has been shown to be a sensitive lung function test in early lung disease. Its usefulness has been demonstrated in cystic fibrosis (CF), particularly in children and adults with mild disease. LCI has been assessed in bronchiectasis and has been found to be significantly different from normal subjects, and to correlate with Forced Expiratory Volume in 1 second (FEV1).
The aim of this study is to test the long term effect of daily lung clearance on LCI, quality of life and exacerbations using the Aerobika oPEP device versus autogenic drainage (AD) in people with bronchiectasis.
50 patients with confirmed bronchiectasis will be enrolled in this study. Participants will be randomized to daily physiotherapy with either Aerobika or Autogenic drainage. Change in LCI, measured before and after one month, will be the primary endpoint of this study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchiectasis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
2 modes of physiotherapy: 1- autogenic drainage; 2- oscillating positive expiratory pressure device
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Autogenic drainage
Arm Type
Active Comparator
Arm Description
Chest physiotherapy by autogenic drainage daily for 15 minutes each day, for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
Arm Title
oPEP
Arm Type
Active Comparator
Arm Description
Chest physiotherapy with an Aerobika oPEP device daily for 15 minutes each day for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
Intervention Type
Device
Intervention Name(s)
oPEP
Other Intervention Name(s)
Aerobika device
Intervention Description
Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
Intervention Type
Behavioral
Intervention Name(s)
Autogenic drainage
Intervention Description
Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
Primary Outcome Measure Information:
Title
Change in LCI
Description
LCI will be determined before intervention and after 1 month and change will be recorded.
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Total score on QOL- B questionnaire
Description
Patients will answer QOL-B questionnaire before and after 1 month of the intervention, and total score will be recorded.
Time Frame
1 month
Title
Score on respiratory domain of QOL-B questionnaire
Description
Patients will answer QOL-B questionnaire before and after 1 month of the intervention, and score on respiratory domain will be recorded.
Time Frame
1 month
Title
FEV1 (% predicted)- difference from baseline
Description
Spirometry will be performed before and after 1 month of the intervention, and change in FEV1 (% of predicted) will be recorded.
Time Frame
1 month
Title
Forced Expiratory Volume (FVC) (% predicted)- difference from baseline
Description
Spirometry will be performed before and after 1 month of the intervention, and change in FVC (% of predicted) will be recorded.
Time Frame
1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
High Resolution chest computerized tomography (HRCT) during stable disease imaging bronchiectasis in at least 2 lung lobes
Sputum production during most days of the year
Stable chronic therapy during last 4 weeks
FEV1 = 70% predicted or higher on spirometry
Able to give informed consent or assent
Age: 18- 80 years
Exclusion Criteria:
An exacerbation during last 4 weeks before randomization
Any change in respiratory medications during the past 4 weeks before randomization
A diagnosis of cystic fibrosis
A diagnosis of primary ciliary dyskinesia
Facility Information:
Facility Name
Carmel Medical Center
City
Haifa
ZIP/Postal Code
3436209
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michal Shteinberg, Md PhD
Phone
972506265846
Email
michalsh4@clalit.org.il
Facility Name
Pulmonology Institute, Carmel Medical Center
City
Haifa
ZIP/Postal Code
34362
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michal Shteinberg, MD, PhD
Phone
97248250517
Email
michal.shteinberg@gmail.com
Phone
97248250517
First Name & Middle Initial & Last Name & Degree
Yochai Adir, MD
First Name & Middle Initial & Last Name & Degree
Michal Shteinberg, MD, PhD
First Name & Middle Initial & Last Name & Degree
Assaf Jacobi, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
22640850
Citation
Flude LJ, Agent P, Bilton D. Chest physiotherapy techniques in bronchiectasis. Clin Chest Med. 2012 Jun;33(2):351-61. doi: 10.1016/j.ccm.2012.02.009. Epub 2012 Apr 4.
Results Reference
background
PubMed Identifier
23397305
Citation
Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, Thamrin C, Arets HG, Aurora P, Fuchs SI, King GG, Lum S, Macleod K, Paiva M, Pillow JJ, Ranganathan S, Ratjen F, Singer F, Sonnappa S, Stocks J, Subbarao P, Thompson BR, Gustafsson PM. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J. 2013 Mar;41(3):507-22. doi: 10.1183/09031936.00069712. Epub 2013 Feb 8. Erratum In: Eur Respir J. 2013 Nov;42(5):1432. Ranganathan, Sarah [corrected to Ranganathan, Sarath].
Results Reference
background
PubMed Identifier
24884343
Citation
Gonem S, Scadding A, Soares M, Singapuri A, Gustafsson P, Ohri C, Range S, Brightling CE, Pavord I, Horsley A, Siddiqui S. Lung clearance index in adults with non-cystic fibrosis bronchiectasis. Respir Res. 2014 May 18;15(1):59. doi: 10.1186/1465-9921-15-59.
Results Reference
result
PubMed Identifier
24428575
Citation
Rowan SA, Bradley JM, Bradbury I, Lawson J, Lynch T, Gustafsson P, Horsley A, O'Neill K, Ennis M, Elborn JS. Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med. 2014 Mar 1;189(5):586-92. doi: 10.1164/rccm.201310-1747OC.
Results Reference
result
Learn more about this trial
Oscillating PEP vs Autogenic Drainage in People With Bronchiectasis
We'll reach out to this number within 24 hrs